**TITLE:**

Protein Kinase C-delta Inhibitor Peptide Formulation Using Gold Nanoparticles

**AUTHORS & AFFILIATIONS:**

Hisato Konoeda1, Hong Yang2, Chengliang Yang1, Chun Xu1, Wei Zhang1, Mingyao Liu1,3

1Latner Thoracic Surgery Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada

2Respiratory Medicine Research Laboratory, Institute of Translation Medicine, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China

3Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

**Corresponding Author:**

Mingyao Liu

mingyao.liu@utoronto.ca

Tel. (416)-581-7501

**Email Addresses of Co-authors:**

Hisato Konoeda Hisato.Konoeda@uhnresearch.ca

Hong Yang hongyang36@gmail.com

Chengliang Yang Cheng-Liang.Yang@uhnresearch.ca

Chun Xu Chun.Xu@uhnresearch.ca

Wei Zhang Wei.Zhang@uhnresearch.ca

**KEYWORDS:**   
Biomaterials, intravenous drug delivery, peptide therapeutics, drug delivery vehicle, amino acid, drug formulation

**SUMMARY:**

We have previously used a gold nanoparticle peptide hybrid to intravenously deliver a synthetic peptide, protein kinase C-delta inhibitor, which reduced ischemia-reperfusion-induced acute lung injury. Here we show the detailed protocol of the drug formulation. Other intracellular peptides can be formulated similarly.

**ABSTRACT:**

Protein kinase C-delta inhibitor (PKCδi) is a promising drug to prevent ischemia-reperfusion-induced organ injury. It is usually conjugated to a cell-penetrating peptide, TAT, for intracellular delivery. However, TAT has shown non-specific biological activities. Gold nanoparticles (GNPs) can be used as drug delivery carriers without recognized toxicity. Therefore, we have used a GNP/peptide hybrid to deliver PKCδi. Two short peptides (P2: CAAAAE and P4: CAAAAW), at a 95:5 ratio, were used to modify the surface properties of GNP. GNPs conjugated with PKCδi (GNP/PKCi) are stable in distilled water, 0.9% NaCl, and phosphate-buffered saline containing bovine serum albumin or fetal bovine serum. Intravenous injection of GNP-PKCi was previously shown to prevent ischemia-reperfusion injury of the lung. This article outlines a protocol to formulate GNP/PKCi and assess the physiochemical properties of GNP/PKCi. We have used similar methods to formulate other peptide-based drugs with GNP. This article will hopefully draw more attention to this novel intracellular drug delivery technology and its applications *in vivo*.

**INTRODUCTION:**

Lung transplantation saves patients with end-stage lung disease1. However, serious complications after lung transplantation remain an obstacle. In the early stages following lung transplantation, primary graft dysfunction is the most harmful complication1, and its primary cause is ischemia-reperfusion (IR)-induced acute lung injury2.

Under cold preservation, metabolism in a donor lung is restricted to a very low level. However, reactive oxygen species and nitric oxide synthesis are activated due to the cessation of blood flow3. After transplantation, blood circulation is restored, and reactive oxygen species and nitric oxide generated during cold ischemia enhance inflammation and cell death, resulting in tissue injury.

To prevent IR injury, a protein kinase Cδ inhibitor (PKCδi) has been used in the heart, brain and lung4-8. These studies showed that PKCδi decreased inflammation and apoptosis during reperfusion. It has also prevented pulmonary IR injury in rats and in a lung transplant model6. PKCδi is usually conjugated with a cell-penetrating peptide, TAT, for intracellular delivery. However, it has been shown that the TAT peptide alone has non-specific biological effects, including promotion of angiogenesis, apoptosis, and inhibition of multiple cytokines9-11. Nanoparticles, small particles ranging from 1 to 100 nm in diameter12, have been explored as candidates in facilitating drug delivery13. In particular, gold nanoparticles (GNPs) are regarded as noninvasive and nontoxic. Therefore, we have developed GNPs as drug delivery carriers for peptide-based drugs14,15.

The surface of GNPs can be manipulated for specific applications such as molecular recognition16,17, chemical sensing18, imaging19, and drug delivery. A GNP/peptide hybrid system has been developed, containing 20 nm GNPs and two short peptides (P2: CAAAAE and P4: CAAAAW) at a 95:5 ratio, to modify the surface properties of GNPs. The P2 peptide, with the negatively charged glutamic acid (E) at the end, stabilizes GNPs in an aqueous solution, and the P4 peptide, with the hydrophobic tryptophan (W) at the end, helps GNPs entrance into cells14. The cysteine (C) residue at the N terminus of these peptides contains a thiol group that can conjugate to the gold surfaces14. This peptide/GNP hybrid was further used to deliver PKCδi (CSFNSYELGSL). The optimized molar ratio of P2:P4 to PKCδi is 47.5:2.5:50. GNPs conjugated with PKCδi (GNP/PKCi) are stable in distilled water, 0.9% NaCl, and phosphate-buffered saline (PBS) containing bovine albumin or fetal bovine serum14. Intravenous injection of GNP/PKCi has been shown to prevent ischemia-reperfusion injury of the lung15. This article outlines a method to formulate GNP/PKCi and describes how to evaluate the physicochemical properties of GNP/PKCi. We have used similar methods to formulate other peptide-based drugs conjugated to GNP20-22. We hope this article will draw more attention to this novel formulation for intracellular drug delivery.

**PROTOCOL:**

**1. Preparation of Peptide Solutions**

* 1. Retrieve the peptides (P2: CAAAAE, P4: CAAAAW, PKCδi: CSFNSYELGSL) from the -20 °C freezer and thaw at room temperature (RT).

NOTE: Keep the bottle closed to prevent moisture from condensing on the peptides.

* 1. Weigh 0.01 g of each peptide on a microscale. Put each peptide into a separate 50 mL conical tube.
  2. Add 18.74 mL of deionized (DI) water to the P2 tube.
  3. Add 16.93 mL of DI water to the P4 tube.
  4. Add 8.21 mL of 50% acetonitrile diluted in DI water to the PKCδi tube.
  5. Vortex the peptide solutions briefly. Put the 50 mL conical tubes in a sonicator (40 MHz) for 5 min.
  6. Bring the peptide solutions to a biosafety cabinet. All peptide solutions prepared should be 1 mM.
  7. Transfer 1 mL of each peptide solution to a new 50 mL conical tube. Add 19 mL of DI water to the tubes of P2 and P4 and add 19 mL of 50% acetonitrile to the PKCδi tube, such that each solution is diluted to 50 µM and stored in its own tube.
  8. Aliquot 1 mL of each 50 µM peptide solution into 1.5 mL microtubes.
  9. Place all aliquots in a -80 °C freezer.

NOTE: Stock solution should be remade each month.

1. **Formulation of GNP/PKCi**
   1. Remove the peptide solutions from the -80 °C freezer. Thaw them at RT. Bring them to a biosafety cabinet.
   2. Add 475 µL of P2, 25 µL of P4, and 500 µL of PKCδi solution to 9 mL of 20 nm GNP solution (7.0 x 1011 particle/mL) in a 15 mL tube.
   3. Exit the biosafety cabinet. Wrap the 15 mL tube with aluminum foil. Leave it on a shaker at RT overnight.
   4. Return the samples to the biosafety cabinet. Aliquot 1 mL of GNP/PKCi into each 1.5 mL microtubes.
   5. Centrifuge the tubes in a micro-centrifuge for 30 min at 15,294 x g at 4 °C.
   6. Remove the supernatant from each tube under a biosafety cabinet.

NOTE: Be careful to remove the supernatant while ensuring that the GNP pellet remains intact and is not aspirated.

* 1. Re-suspend the pellet in the desired solvent according to the concentration required. Applicable solvents can be DI water, PBS, and 0.9% NaCl.

NOTE: Starting from 1 mL of GNP/PKCi, the GNP pellet contains 6.3 x 1011 particles, based on the GNP concentration provided by the manufacturer. To administer 1.3 x 1012 particles in 500 µL of 0.9% NaCl, we add 232 µL of 0.9% NaCl to each of three pellets. After pooling them together, we can then collect 500 µL of GNP/PKCi solution.

NOTE: Mix the desired solvent well before diluting the GNP/PKCi pellet, otherwise the GNP/PKCi will aggregate.

1. **Assessment of GNP/PKCi Hybrid Solubility**
   1. Pour 0.5 mL of GNP/PKCi solution into an acryl cuvette. Place the acryl cuvette on a UV-Vis spectrophotometer and test the peak absorption15.

**REPRESENTATIVE RESULTS:**

Care should be taken to evaluate the biophysical properties of the GNP/PKCi hybrid, as GNP tends to aggregate in a solvent. When GNP is aggregated, the color of the solution changes from pink to purple (**Figure 1A**). The UV-Vis spectrophotometer is able to detect changes more sensitively. If the GNP/PKCi is not aggregated, the peak of absorption should be at 525 nm (**Figure 1B**). If the GNP is aggregated, the peak of absorption will be shifted to the right. As an alternate method of analysis, when aggregates have formed, Δoptical density (ΔOD = OD at 525 nm - OD at 440 nm) decreases (**Figure 1C**).

**Figure Legends:**

**Figure 1: Quality of GNP/PKCi.** (**A**) Properly prepared GNP/PKCi is pink in color (left). Aggregated GNP/PKCi appears light purple (right). (**B**) Good GNP/PKCi preparation is stable in water, PBS, or 0.9% NaCl solution. Readings on a UV-Vis spectrometer indicated that the peak of absorption was at 525 nm in all solutions. (C) An example of good and bad GNP/PKCi preparations. When the GNP was aggregated, the peak of absorption was shifted to the right. Moreover, ΔOD decreased.

**DISCUSSION:**

To ensure proper formulation, it is crucial that the PKCδi solution undergoes the sonication step outlined in step 1.6 of the protocol. The PKCδi peptide sequence contains hydrophobic moieties, so a sonicator assists in dissolving PKCi in the 50% acetonitrile solution. In addition, it is very important to mix the solvent meticulously, as outlined in step 2.7. The GNP/PKCi hybrid will not be well-formulated if these steps are not done properly due to aggregation of the PKCδi peptide23.

GNP-based drug formulation provides several advantages. First, GNPs can be easily synthesized in well-controlled sizes, ranging from a few nanometers to ~100 nm24. Usually, smaller GNPs can deliver drugs into cells more efficiently than larger ones, since they can more easily diffuse into their target regions25. Second, GNPs are non-toxic *in vitro* and *in vivo*26, rendering them safe drug carriers. Third, hydrophobic drugs can be loaded onto the modified GNPs27. Fourth, the surface chemistry of GNPs is readily modified for specific applications. In our studies, two short peptides were used to modify the GNP surface14, stabilize them in physiological conditions, and impart new bioactivities15. The peptides were thoughtfully designed, with three regions including gold binding, spacing, and functional regions14. Specifically, the N terminus of the peptide has a cysteine (C) residue containing a thiol group that can bind with gold. The middle portion has four hydrophobic alanine residues to promote peptide assembly into a densely packed monolayer on the GNPs. The amino acid at the C terminus is a functional amino acid pointing outward, which can be used to manipulate the surface properties of the GNPs. The 95:5 ratio of these two peptides was systemically selected in a previous study14. The ratio between PKCi and P2/P4 peptides was also systemically tested and selected15.

The GNP drug delivery system does have its limitations. GNPs are not cell type- or tissue-specific. GNPs are mainly accumulated in the lung, liver, and spleen after intravenous administration28-30. So far, this formula has only been tested in cell cultures and small animal models15. For translation to clinical applications, further studies on larger animal models are needed, and the system’s pharmacokinetics, tissue distribution, and potential toxicity must be determined.

**ACKNOWLEDGMENTS:**

This work is supported by research grants from Canadian Institutes of Health Research (PJT-148847), Ministry of Research and Innovation of Ontario (RE-08-029), and Canada First Research of Excellence Program, Medicine by Design at University of Toronto. Dr. Mingyao Liu is James and Mary Davie Chair in Lung Injury, Repair, and Regeneration. We thank Annette Gower for help with editing the manuscript.

**DISCLOSURES:**

The authors have nothing to disclose on this project.

**REFERENCES**:

1 Yusen, R. D., *et al.* The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report--2014; focus theme: retransplantation. *The Journal of Heart and Lung Transplantation.* **33** (10), 1009-1024, doi:10.1016/j.healun.2014.08.004, (2014).

2 Lee, J. C., Christie, J. D., Keshavjee, S. Primary graft dysfunction: definition, risk factors, short- and long-term outcomes. *Seminars in Respiratory and Critical Care Medicine.* **31** (2), 161-171, doi:10.1055/s-0030-1249111, (2010).

3 Chatterjee, S., Nieman, G. F., Christie, J. D., Fisher, A. B. Shear stress-related mechanosignaling with lung ischemia: lessons from basic research can inform lung transplantation. *American Journal of Physiology-Lung Cellular and Molecular Physiology.* **307** (9), L668-680, doi:10.1152/ajplung.00198.2014, (2014).

4 Inagaki, K., *et al.* Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. *Circulation.* **108** (19), 2304-2307, doi:10.1161/01.CIR.0000101682.24138.36, (2003).

5 Lincoff, A. M., *et al.* Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. *European Heart Journal.* **35** (37), 2516-2523, doi:10.1093/eurheartj/ehu177, (2014).

6 Kim, H.*, et al.* deltaV1-1 Reduces Pulmonary Ischemia Reperfusion-Induced Lung Injury by Inhibiting Necrosis and Mitochondrial Localization of PKCdelta and p53. *American Journal of Transplantation.* **16** (1), 83-98, doi:10.1111/ajt.13445, (2016).

7 Lin, H. W., *et al.* Derangements of post-ischemic cerebral blood flow by protein kinase C delta. *Neuroscience.* **171** (2), 566-576, doi:10.1016/j.neuroscience.2010.08.058, (2010).

8 Lin, H. W., *et al.* Protein kinase C delta modulates endothelial nitric oxide synthase after cardiac arrest. *Journal of Cerebral Blood Flow Metabolism.* **34** (4), 613-620, doi:10.1038/jcbfm.2013.232, (2014).

9 Albini, A., *et al.* HIV-tat protein is a heparin-binding angiogenic growth factor. *Oncogene.* **12** (2), 289-297 (1996).

10 Kim, H., Moodley, S., Liu, M. TAT cell-penetrating peptide modulates inflammatory response and apoptosis in human lung epithelial cells. *Drug Delivery and Translational Research.* **5** (3), 275-278, doi:10.1007/s13346-015-0230-6, (2015).

11 Lee, D., Pacheco, S., Liu, M. Biological effects of Tat cell-penetrating peptide: a multifunctional Trojan horse? *Nanomedicine (Lond).* **9** (1), 5-7, doi:10.2217/nnm.13.193, (2014).

12 Auffan, M., *et al.* Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective. *Nature Nanotechnology.* **4** (10), 634-641, doi:10.1038/nnano.2009.242, (2009).

13 Ghosh, P., Han, G., De, M., Kim, C. K., Rotello, V. M. Gold nanoparticles in delivery applications. *Advanced Drug Delivery Reviews* **60** (11), 1307-1315, doi:10.1016/j.addr.2008.03.016, (2008).

14 Yang, H., Fung, S. Y., Liu, M. Programming the cellular uptake of physiologically stable peptide-gold nanoparticle hybrids with single amino acids. *Angewandte Chemie International Edition.* **50** (41), 9643-9646, doi:10.1002/anie.201102911, (2011).

15 Lee, D., *et al.* Effective delivery of a rationally designed intracellular peptide drug with gold nanoparticle-peptide hybrids. *Nanoscale.* **7** (29), 12356-12360, doi:10.1039/c5nr02377g, (2015).

16 Cheng, M. M., *et al.* Nanotechnologies for biomolecular detection and medical diagnostics. *Current Opinion in Chemical Biology.* **10** (1), 11-19, doi:10.1016/j.cbpa.2006.01.006, (2006).

17 Rosi, N. L., Mirkin, C. A. Nanostructures in biodiagnostics. *Chemical Reviews.* **105** (4), 1547-1562, doi:10.1021/cr030067f, (2005).

18 Saha, K., Agasti, S. S., Kim, C., Li, X., Rotello, V. M. Gold nanoparticles in chemical and biological sensing. *Chemical Reviews.* **112** (5), 2739-2779, doi:10.1021/cr2001178, (2012).

19 Boisselier, E., Astruc, D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. *Chemical Society Reviews.* **38** (6), 1759-1782, doi:10.1039/b806051g, (2009).

20 Yang, H., *et al.* Amino Acid-Dependent Attenuation of Toll-like Receptor Signaling by Peptide-Gold Nanoparticle Hybrids. *ACS Nano.* **9** (7), 6774-6784, doi:10.1021/nn505634h, (2015).

21 Yang, H., *et al.* Endosomal pH modulation by peptide-gold nanoparticle hybrids enables potent anti-inflammatory activity in phagocytic immune cells. *Biomaterials.* **111,** 90-102, doi:10.1016/j.biomaterials.2016.09.032, (2016).

22 Yang, H., *et al.* Amino Acid Structure Determines the Immune Responses Generated by Peptide-Gold Nanoparticle Hybrids. *Particle & Particle Systems Characterization.* **30** (12), 1039-1043, doi:10.1002/ppsc.201300213, (2013).

23 Pamies, R., *et al.* Aggregation behaviour of gold nanoparticles in saline aqueous media. *Journal of Nanoparticle Research.* **16** (4), doi:10.1007/s11051-014-2376-4, (2014).

24 Kimling, J., *et al.* Turkevich method for gold nanoparticle synthesis revisited. *The Journal of Physical Chemistry B.* **110** (32), 15700-15707, doi:10.1021/jp061667w, (2006).

25 Perrault, S. D., Walkey, C., Jennings, T., Fischer, H. C., Chan, W. C. Mediating tumor targeting efficiency of nanoparticles through design. *Nano Letters.* **9** (5), 1909-1915, doi:10.1021/nl900031y, (2009).

26 Connor, E. E., Mwamuka, J., Gole, A., Murphy, C. J., Wyatt, M. D. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. *Small.* **1** (3), 325-327, doi:10.1002/smll.200400093, (2005).

27 Kim, C. K., *et al.* Entrapment of Hydrophobic Drugs in Nanoparticle Monolayers with Efficient Release into Cancer Cells. *Journal of the American Chemical Society.* **131** (4), 1360-+, doi:10.1021/ja808137c, (2009).

28 Sonavane, G., Tomoda, K., Makino, K. Biodistribution of colloidal gold nanoparticles after intravenous administration: Effect of particle size. *Colloids and Surfaces B-Biointerfaces.* **66** (2), 274-280, doi:10.1016/j.colsurfb.2008.07.004, (2008).

29 Balasubramanian, S. K., *et al.* Biodistribution of gold nanoparticles and gene expression changes in the liver and spleen after intravenous administration in rats. *Biomaterials.* **31** (8), 2034-2042, doi:10.1016/j.biomaterials.2009.11.079, (2010).

30 Lipka, J., *et al.* Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. *Biomaterials.* **31** (25), 6574-6581, doi:10.1016/j.biomaterials.2010.05.009, (2010).